Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women.

Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT.

Menopause. 2007 May-Jun;14(3 Pt 1):481-8.

2.

Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women.

Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T.

Am J Clin Nutr. 2000 Sep;72(3):844-52.

3.

Decreased bone resorption with soy isoflavone supplementation in postmenopausal women.

Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E.

J Womens Health (Larchmt). 2004 Nov;13(9):1000-7.

PMID:
15665657
5.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
6.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.

J Clin Endocrinol Metab. 2013 Dec;98(12):4727-35. doi: 10.1210/jc.2013-2020. Epub 2013 Sep 24.

PMID:
24064689
7.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
8.

Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.

Guo CY, Weetman AP, Eastell R.

Clin Endocrinol (Oxf). 1997 Mar;46(3):301-7.

PMID:
9156039
9.

One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women.

Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C.

Nutr J. 2005 Feb 23;4:8.

10.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.

J Clin Endocrinol Metab. 2008 Jun;93(6):2149-57. doi: 10.1210/jc.2007-2814. Epub 2008 Apr 1.

PMID:
18381571
11.

Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women--a 2-year randomized, double-blind, placebo-controlled trial.

Vupadhyayula PM, Gallagher JC, Templin T, Logsdon SM, Smith LM.

Menopause. 2009 Mar-Apr;16(2):320-8. doi: 10.1097/gme.0b013e3181844893.

PMID:
19169168
12.

Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial.

Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT.

JAMA. 2004 Jul 7;292(1):65-74.

PMID:
15238592
14.
15.

Soy isoflavones: no effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year.

Anderson JJ, Chen X, Boass A, Symons M, Kohlmeier M, Renner JB, Garner SC.

J Am Coll Nutr. 2002 Oct;21(5):388-93.

PMID:
12356779
16.

A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.

Rogers A, Glover SJ, Eastell R.

Bone. 2009 Dec;45(6):1044-52. doi: 10.1016/j.bone.2009.07.089. Epub 2009 Aug 7.

PMID:
19665601
17.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.

PMID:
11238495
18.

Soy protein consumption and bone mass in early postmenopausal Chinese women.

Ho SC, Woo J, Lam S, Chen Y, Sham A, Lau J.

Osteoporos Int. 2003 Oct;14(10):835-42. Epub 2003 Aug 14. Review.

PMID:
12920508
19.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

20.

Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study.

Nabipour I, Larijani B, Beigi S, Jafari SM, Amiri M, Assadi M, Pazoki R, Amiri Z, Sanjdideh Z.

Menopause. 2008 Sep-Oct;15(5):934-9. doi: 10.1097/gme.0b013e31816665a7.

PMID:
18451743

Supplemental Content

Support Center